Loading…
← CockpitCompetitor Analysis › LMRI Lumexa Imaging Holdings, Inc.Open in the cockpit ↗

Lumexa Imaging Holdings, Inc.LMRICompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services
Momentum leader 97
Mkt cap
$1.35B
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$5.37M
20-day average traded
Fwd P/E
16.0×
forward earnings
ROIC−WACC
-7.0 pp
WACC 8.2%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · USD$14.01
1D-4.2%
1W-12.2%
1M+31.2%
3M+19.9%
6M+89.3%
YTD-24.3%
1Yn/a
ATR %5.7%
Beta1.56
52w lowhigh28.0% off high

What Lumexa Imaging does

Employees: 5,019

Lumexa Imaging at a glance

Size Lumexa Imaging (LMRI) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.35B, the 2045th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.01 on 18 Nov 2026.

Performance Over six months the shares gained 89.3%, against +14.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 7.8% over the last twelve months (peer median +6.9%); the operating margin is 2.2% (peer median 6.2%).

Valuation It trades at 16.0× forward earnings against a peer median of 29.4× (5th cheapest of 16).

Capital Return on invested capital runs 7.0 points below its cost of capital (8.2% WACC).

Short interest Short interest is 1.9% of the free float (30 Oct 2026).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026LMRI 171Peer median 113
Six months, rebased to 100: Lumexa Imaging against the median of its 20 peers (local-currency closes).

Lumexa Imaging financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue$1.06B$1.02B$949M$936M
Revenue growth—+8%+1%—
Gross profit$120M$117M$54.1M$42.3M
EBITDA$83.2M$82.6M$40.9M$59.2M
Net income-$17.1M-$47.1M-$94.1M-$122M
Free cash flown/a-$6.40M$13.0M$13.5M
Capital expendituren/a$23.5M$27.8M$24.0M
Total debt$977M$963M$1.31B$1.30B

Quarterly statements and history in the cockpit →

Lumexa Imaging competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%1833CLARIDIAUSPH4544PNTGOPKMETROPOLISTDOCAGLNUTXWGSGDRXAMBEASNDAPSNLVIJAYA300244EMEIS688315LMRI6-month return →1-month return →
Up and to the right = strong over both horizons. Lumexa Imaging is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×1833CLARIDIAUSPH4544PNTGMETROPOLISAGLNUTXWGSGDRXAMBEAVIJAYA300244688315LMRIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lumexa Imaging is the large dot.

Lumexa Imaging competitors and peer comparison

How Lumexa Imaging compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lumexa Imaging against its 20 peers (data as of 18 Nov 2026)
MeasureLMRIPeer medianRank in peer set
1-month return+31.2%-1.6%highest of 21
6-month return+89.3%+14.4%highest of 21
Distance from 52-week high-28.0%-22.2%6th lowest of 21
Revenue growth (TTM)+7.8%+6.9%11th highest of 21
Operating margin2.2%6.2%7th lowest of 21
Forward P/E16.0×29.4×5th cheapest of 16
ROIC minus cost of capital-7.0 pp-3.1 pp6th lowest of 20
EV / EBITDA26.8×10.7×3rd most expensive of 14
Net debt / EBITDA10.7×1.7×2nd most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%63.0×40.4%+16.7%
Dian Diagnostics 300244.SZChina$1.70B+1%-5%9%21.8×0.3%-1.1%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%n/a21.2%+8.5%
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%

Questions

Which companies are Lumexa Imaging's closest peers?
The cockpit's peer set: Ping An Healthcare and Technology (1833.HK), Clariane (CLARI.PA), Diagnostyka (DIA.WA), U.S. Physical Therapy (USPH), H.U.Group (4544.T), Pennant (PNTG), OPKO Health (OPK), Metropolis Healthcare (METROPOLIS.NS).
Is Lumexa Imaging expensive compared with its peers?
On forward p/e it trades at 16.0× against a peer median of 29.4×, 5th cheapest of 16 in its peer set.
How has Lumexa Imaging stock performed?
Over six months to 18 Nov 2026 the shares returned +89.3% against +14.4% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.